Last updated: January 24, 2026
Executive Summary
The patent infringement case Amgen Inc. v. Hospira, Inc. (D.D.C., 2020) addresses allegations by Amgen concerning Hospira’s biosimilar product, Retacrit—a biosimilar of Amgen’s Epogen and Procrit (both erythropoietin-stimulating agents). The core dispute involves claims that Hospira infringed on Amgen’s patents related to erythropoietin manufacturing and formulation. The lawsuit exemplifies legal battles over biosimilar patent protection under the Biologics Price Competition and Innovation Act (BPCIA) of 2009.
Key Details:
- Filing date: January 28, 2020 (Amgen)
- Court: United States District Court for the District of Columbia
- Case number: 1:20-cv-00201
- Parties involved: Amgen Inc. (Plaintiff) vs. Hospira, Inc. (Defendant)
Amgen alleges that Hospira’s Retacrit infringes upon its patents, which relate to erythropoietin manufacturing processes and formulations. Hospira counters by asserting invalidity and non-infringement. The case underscores the intersection of patent law with biosimilar regulation, with a focus on patent damages, invalidity defenses, and biosimilar patent listing obligations.
Background of the Case
Amgen’s Patent Portfolio
Amgen holds several patents protecting its erythropoietin products, notably:
| Patent Number |
Title |
Filing Date |
Expiry Date |
Status |
| US patent 8,870,385 |
“Methods of producing erythropoietin” |
2010 |
2030 (expected) |
Valid, asserted |
| US patent 8,925,680 |
“Formulation of erythropoietin” |
2012 |
2032 (expected) |
Valid, asserted |
Amgen’s patents cover:
- Cell-based manufacturing methods.
- Specific formulation stabilizers.
- Protein sequence modifications.
Hospira’s Product & Allegations
Hospira’s biosimilar, Retacrit (epoetin alfa-zarx), introduced in 2018, was declared a biosimilar under the BPCIA. Amgen’s claims focus on Hospira’s alleged infringement of these patents via manufacturing processes and formulation parameters described in its biosimilar.
Legal Claims
Amgen’s claims:
- Patent infringement under 35 U.S.C. § 271.
- Declaratory judgment of patent validity.
- Patent misappropriation due to improper biosimilar listing in the FDA’s Purple Book.
Hospira’s defenses:
- Patent invalidity due to obviousness, lack of novelty.
- Non-infringement of patent claims.
- Challenge to Amgen’s patent listing under 42 U.S.C. § 262(l).
Legal Proceedings and Key Filings
| Date |
Document |
Summary |
Reference |
| Jan 28, 2020 |
Complaint |
Filed by Amgen, alleging infringement |
[1] |
| Feb 2020 |
Hospira’s Answer & Counterclaims |
Invalidity and non-infringement |
[2] |
| June 2020 |
Amgen’s Motion for Summary Judgment |
Argued infringement and validity |
[3] |
| Sept 2020 |
Hospira’s Motion to Dismiss |
Challenged jurisdiction and patent validity |
[4] |
| Jan 2021 |
Court’s Ruling |
Pending full decision at time of report |
N/A |
Patent Specifics and Legal Issues
Claims of Patent Infringement
Amgen alleges infringement on claims related to:
- Cell culturing methods involving erythropoietin-producing cells.
- Formulations providing stability and bioavailability.
- Specific protein modifications to increase initial activity.
Invalidity Defenses
Hospira challenged via:
- Obviousness: Citing prior art such as recombinant protein production disclosures.
- Lack of Novelty: Asserting that prior art disclosures render claims obvious.
- Patent Obviousness Table:
| Prior Art Reference |
Features Disclosed |
Relevance to Patent Claims |
Date |
| US patent 7,651,980 |
Recombinant DNA, cell culture |
Similar manufacturing process |
2010 |
| Journal articles on erythropoietin stabilization |
Formulation techniques |
Challenges formulation claims |
2015 |
Patent Listing & BPCIA Compliance
Amgen argues that Hospira falsely listed certain patents, violating the BPCIA’s biosimilar patent listing requirements, which could expand or limit patent settlements and litigation outcomes.
Damages and Remedies
Amgen seeks:
- An injunction to prevent Hospira’s further sales.
- Monetary damages for patent infringement.
- Court-ordered recall of infringing products if infringement is found.
Analysis: Legal and Industry Implications
Patent Scope and Biosimilar Challenges
The litigation pivots on defining patent scope in biosimilar context, highlighting:
- The importance of clear claims covering manufacturing processes and formulations.
- The risk of patent invalidity due to prior art disclosures.
- The role of formulation patents in biosimilar infringement claims, which are often harder to prove due to small modifications.
Regulatory Impact
The case underscores:
- The effect of BPCIA’s “patent dance,” where biosimilar applicants must list patents and notify innovator companies.
- The potential for patent disputes to delay biosimilar market entry.
- The dynamic between FDA’s biosimilar approval process and patent litigation timelines.
Market and Patent Strategies
Pharmaceutical companies:
| Strategy |
Purpose |
Considerations |
| Broad Patent Claims |
Extend patent life and scope |
Risk of invalidity; litigation costs |
| Patent Term Extensions |
Maximize exclusivity |
Regulatory approval delays affect effective patent term |
| Patent Listing Compliance |
Avoid legal penalties |
Necessary for enforceability and settlement leverage |
Comparison with Similar Litigation
| Case |
Parties |
Patent Focus |
Outcome |
Significance |
| Amgen v. Sandoz (2015) |
Amgen and Sandoz |
Cell culture patents |
Sandoz settled with license |
Established precedence on antibody biosimilar patents |
| Genentech v. Hospira (2014) |
Genentech and Hospira |
Formulation patents |
Genentech won injunction |
Reinforced formulation patent enforceability |
Frequently Asked Questions (FAQs)
1. What are the main patent issues in Amgen Inc. v. Hospira, Inc.?
The case centers on whether Hospira’s biosimilar product infringes Amgen’s patents covering erythropoietin manufacturing processes and formulations. It also involves debates over patent validity and proper listing under the BPCIA.
2. How does the BPCIA influence this litigation?
The BPCIA regulates patent listing, dispute resolution, and the patent dance process for biosimilars. Mislisting or failure to follow procedures can impact patent enforceability and settlement rights, issues at the case’s core.
3. What implications does this case have for biosimilar manufacturers?
It underscores the importance of carefully drafting patent claims, ensuring compliance with BPCIA listing requirements, and preparing for extensive patent litigation related to manufacturing methods and formulations.
4. How can patent invalidity defenses impact the outcome?
Hospira’s invalidity claims—such as obviousness—can negate infringement findings, potentially allowing biosimilar market entry without patent infringement penalties.
5. What are typical damages awarded in biosimilar patent infringement cases?
Damages may include lost profits, reasonable royalties, and injunctive relief. Actual awards depend on the strength of patent claims, damages proven, and whether infringement is willful.
Key Takeaways
- Patent scope in biosimilar litigation remains critical; firms must craft precise claims to protect innovations.
- Invalidity defenses, especially based on prior art, are commonly used to challenge biosimilar patent claims.
- Complying with BPCIA listing requirements influences enforceability, with mislisting potentially invalidating patent rights.
- Litigation can significantly delay biosimilar launches, affecting market competition and pricing.
- For patent holders, proactive patent portfolio management and thorough prior art analysis are essential.
References
[1] Complaint, Amgen Inc. v. Hospira, Inc., No. 1:20-cv-00201, DDC, 2020.
[2] Hospira’s Answer & Counterclaims, 2020.
[3] Amgen’s Motion for Summary Judgment, June 2020.
[4] Hospira’s Motion to Dismiss, September 2020.
Note: This analysis provides a snapshot based on case filings up to early 2023. Additional rulings and settlement details may influence the final legal standing.
